Next Article in Journal
Briarenolides F and G, New Briarane Diterpenoids from a Briareum sp. Octocoral
Previous Article in Journal
Biochemical Studies of the Lagunamides, Potent Cytotoxic Cyclic Depsipeptides from the Marine Cyanobacterium Lyngbya majuscula
Mar. Drugs 2012, 10(5), 1138-1155; doi:10.3390/md10051138
Article

Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog

1,†
,
1,†
,
1
,
1
,
2
,
2
,
2
,
3,4
,
1,3,*  and 1,3,*
Received: 30 March 2012 / Revised: 2 May 2012 / Accepted: 16 May 2012 / Published: 23 May 2012
View Full-Text   |   Download PDF [1025 KB, uploaded 24 February 2015]   |   Browse Figures

Abstract

We have recently designed and synthesized a novel iminoquinone anticancer agent, 7-(4-fluorobenzylamino)-1,3,4,8-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one (FBA-TPQ) and initiated its preclinical development. Herein we investigated its efficacy, safety, and pharmacokinetics in in vitro and in vivo models of human pancreatic cancer. Our results demonstrated that FBA-TPQ inhibited pancreatic cancer cell growth, induced apoptosis, and caused cell cycle arrest in vitro. It inhibited the growth of xenograft tumors with minimal host toxicity. To facilitate future preclinical and clinical development of the agent, we also developed and validated a Rapid Resolution Liquid Chromatography (RRLC) method for quantitative analysis of FBA-TPQ in plasma and tissue samples. The method was found to be precise, accurate, and specific. Using this method, we carried out in vitro and in vivo evaluations of the pharmacological properties of FBA-TPQ, including stability in plasma, plasma protein binding, metabolism by S9 enzymes, plasma pharmacokinetics, and tissue distribution. Our results indicate that FBA-TPQ is a potential therapeutic agent for pancreatic cancer, providing a basis for future preclinical and clinical development.
Keywords: pancreatic cancer; marine anticancer agents; RRLC; pharmacokinetics pancreatic cancer; marine anticancer agents; RRLC; pharmacokinetics
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Zhang, X.; Xu, H.; Zhang, X.; Voruganti, S.; Murugesan, S.; Nadkarni, D.H.; Velu, S.E.; Wang, M.-H.; Wang, W.; Zhang, R. Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog. Mar. Drugs 2012, 10, 1138-1155.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert